Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib

European Radiology

Volumn 25, Issue 2, 2015, Pages 380-390

  Corona Villalobos, Celia Pamela ^a   Halappa, Vivek Gowdra ^a   Geschwind, Jean Francois H ^a   Bonekamp, Susanne ^a   Reyes, Diane ^a   Cosgrove, David ^a   Pawlik, Timothy M ^a   Kamel, Ihab R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DEB TACE; Diffusion weighted MRI; Sorafenib; Treatment response; Volumetric functional MRI

Indexed keywords

DOXORUBICIN; GADOLINIUM PENTETATE MEGLUMINE; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DELAYED RELEASE FORMULATION; NICOTINAMIDE; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DOXORUBICIN ELUTING BEAD TRANSARTERIAL CHEMOEMBOLIZATION; DRUG DELIVERY SYSTEM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; TREATMENT RESPONSE; VOLUMETRY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; EPIDEMIOLOGY; FEMALE; FOLLOW UP; LIVER NEOPLASMS; MALE; MARYLAND; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TIME FACTOR; TRENDS; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MARYLAND; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL RATE; TIME FACTORS; TUMOR BURDEN;

EID: 84920846904     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-014-3412-6     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156
2. Befeler AS, Di Bisceglie AM (2002) Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122:1609–1619
3. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524
4. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
5. Camma C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54
6. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442
7. Reyes DK, Vossen JA, Kamel IR et al (2009) Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 15:526–532
8. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109
9. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW (2008) Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 49:523–529
10. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10:2878–2882
11. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29:3960–3967
12. Lencioni R, de Baere T, Burrel M et al (2012) Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol 35:980–985
13. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250:466–473
14. Kamel IR, Bluemke DA, Eng J et al (2006) The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17:505–512
15. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60
16. Halappa VG, Bonekamp S, Corona-Villalobos CP et al (2012) Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 264:285–294
17. Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S et al (2013) Neuroendocrine liver metastasis treated by using intraarterial therapy: Volumetric functional imaging biomarkers of early tumor response and survival. Radiology 266:502–513
18. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR (2011) Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 260:752–761
19. Bonekamp S, Halappa VG, Geschwind JF et al (2013) Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. part II. response stratification using volumetric functional criteria after intraarterial therapy. Radiology. doi:10.1148/radiol.13121637
20. Galizia MS, Tore HG, Chalian H, McCarthy R, Salem R, Yaghmai V (2012) MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques. Acad Radiol 19:48–54
21. Liapi E, Geschwind JF (2011) Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 34:37–49
22. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
23. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 35:421–430
24. Grady L (2006) Random walks for image segmentation. IEEE Trans Pattern Anal Mach Intell 28:1768–1783
25. Bonekamp S, Li Z, Geschwind JF et al (2013) Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. identification and validation of volumetric functional response criteria. Radiology. doi:10.1148/radiol.13122307
26. Lewin M, Fartoux L, Vignaud A, Arrive L, Menu Y, Rosmorduc O (2011) The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol 21:281–290
27. Schraml C, Schwenzer NF, Martirosian P et al (2009) Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 193:W301-7. doi:10.2214/AJR.08.2289
28. Takayasu K, Arii S, Matsuo N et al (2000) Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 175:699–704
29. Li Z, Bonekamp S, Halappa VG et al (2012) Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology 264:97–109
30. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943
31. Georgiades C, Geschwind JF, Harrison N et al (2012) Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265:115–123
32. Bonekamp D, Bonekamp S, Halappa VG et al (2013) Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. doi:10.1016/j.ejrad.2013.11.016
33. Riaz A, Miller FH, Kulik LM et al (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 303:1062–1069